Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: The real concerns should be....

I'll have to look at the Q again tonight. They should certainly reword their initial press release. That particular quote is still fresh on my mind. It certainly doesn't give investors or potential investors, the impression that licensing activity is on going. The word "resumption" is fairly straight forward.

Resumption: to return to or begin again after interruption.

A misleading statement at best. A subtle attempt to lower the S/P? How would you explain their choice of wording in the PR? I'll look at the Q again.

Share
New Message
Please login to post a reply